5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant sunitinib in patients with high-risk renal cell carcinoma: Safety, therapy management, and patient-reported outcomes in the S-TRAC trial
    Journal Article

    Staehler, M.; Motzer, R. J.; George, D. J.; Pandha, H. S.; Donskov, F.; Escudier, B.; Pantuck, A. J.; Patel, A.; DeAnnuntis, L.; Bhattacharyya, H.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Schmidinger, M.; Tannir, N. M.; Powles, T.; Escudier, B. J.; Donskov, F.; Grünwald, V.; Sternberg, C. N.; Schoffski, P.; Szczylik, C.; Peltola, K. J.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Bergmann, L.; Donskov, F.; Motzer, R. J.; Voog, E.; Hovey, E. J.; Grüllich, C.; Nott, L. M.; Cuff, K. E.; Gil, T.; Jensen, N. V.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Grüllich, C.; Powles, T.; Motzer, R. J.; George, D. J.; Jonasch, E.; Pal, S. K.; Tannir, N. M.; Signoretti, S.; Mai, T. H.; Scheffold, C.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Immunotherapy for urothelial cancer: Current strategies, new directions, and biomarker approaches
    Meeting Abstract

    Rosenberg, J.
    International Journal of Urology (2018)

    Fulltext@MSK | Save
  • Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial
    Meeting Abstract

    Grnüwald, V.; Cella, D.; Escudier, B. J.; Hammers, H. J.; George, S.; Nathan, P.; Grimm, M. O.; Rini, B. I.; Doan, J.; Ivanescu, C.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Grüllich, C.; Motzer, R. J.; Powles, T.; Atkins, M.; Escudier, B. J.; McDermott, D.; Suarez, C.; Bracarda, S.; Stadler, W.; Donskov, F.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial
    Journal Article

    Li, B. T.; Shen, R. L.; Buonocore, D.; Olah, Z. T.; Ni, A.; Ginsberg, M. S.; Ulaner, G. A.; Offin, M.; Feldman, D.; Hembrough, T.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
    Journal Article

    Rodrigues, D. N.; Rescigno, P.; Liu, D.; Yuan, W.; Carreira, S.; Lambros, M. B.; Seed, G.; Mateo, J.; Riisnaes, R.; Mullane, S.; more...
    Journal of Clinical Investigation (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: A phase 2 clinical trial
    Journal Article

    Autio, K. A.; Dreicer, R.; Anderson, J.; Garcia, J. A.; Alva, A.; Hart, L. L.; Milowsky, M. I.; Posadas, E. M.; Ryan, C. J.; Graf, R. P.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save